Euroopa Liit - eesti - EMA (European Medicines Agency)

bayer ag - iloprost - hüpertensioon, kopsuvähk - antitrombootilised ained - uuringu võimekuse ja sümptomite parandamiseks primaarse pulmonaalse hüpertensiooniga patsientidel, mis on klassifitseeritud new yorgi südameühendite funktsionaalklassiks iii.

Eesti - eesti - Ravimiamet

first pharma oÜ - venlafaksiin - toimeainet prolongeeritult vabastav kõvakapsel - 150mg 20tk; 150mg 98tk; 150mg 250tk; 150mg 100tk; 150mg 50tk; 150mg 10tk; 150mg 14tk; 150mg 28tk

Eesti - eesti - Ravimiamet

krka d.d. novo mesto - venlafaksiin - toimeainet prolongeeritult vabastav kõvakapsel - 150mg 20tk; 150mg 50tk; 150mg 100tk; 150mg 28tk; 150mg 112tk; 150mg 30tk; 150mg 10tk

Eesti - eesti - Ravimiamet

krka d.d. novo mesto - venlafaksiin - toimeainet prolongeeritult vabastav kõvakapsel - 37,5mg 14tk; 37,5mg 20tk; 37,5mg 112tk; 37,5mg 30tk; 37,5mg 50tk; 37,5mg 10tk

Eesti - eesti - Ravimiamet

krka d.d. novo mesto - venlafaksiin - toimeainet prolongeeritult vabastav kõvakapsel - 75mg 50tk; 75mg 100tk; 75mg 98tk; 75mg 28tk; 75mg 14tk; 75mg 250tk; 75mg 10tk; 75mg 20tk

Eesti - eesti - Ravimiamet

ideal trade links uab - venlafaksiin - toimeainet prolongeeritult vabastav kõvakapsel - 75mg 30tk

Eesti - eesti - Ravimiamet

ideal trade links uab - venlafaksiin - toimeainet prolongeeritult vabastav kõvakapsel - 150mg 30tk

Eesti - eesti - Ravimiamet

ideal trade links uab - venlafaksiin - toimeainet prolongeeritult vabastav kõvakapsel - 75mg 30tk

Eesti - eesti - Ravimiamet

ideal trade links uab - venlafaksiin - toimeainet prolongeeritult vabastav kõvakapsel - 150mg 30tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaktsiinid - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.